<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39431651</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2228-7809</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of research in health sciences</Title><ISOAbbreviation>J Res Health Sci</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis.</ArticleTitle><Pagination><StartPage>e00626</StartPage><MedlinePgn>e00626</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.34172/jrhs.2024.161</ELocationID><ELocationID EIdType="pii" ValidYN="Y">e00626</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is a viral disease caused by the <i>SARS-CoV-2</i>, leading to several variants. This study aimed to examine the effectiveness of booster doses against the Delta and Omicron variants over different follow-up times. <b>Study Design:</b> This was a longitudinal meta-analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Searches were performed in PubMed, Cochrane Library, Scopus, and Web of Science databases, and eighty studies were selected for investigation. The analyses were separately performed on the unvaccinated control group (UNVCG) and the complete two doses of the vaccine control group (C2DCG) against Delta and Omicron variants. Three outcomes were examined, including symptomatic infection, hospitalization, and death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Vaccine effectiveness (VE) in UNVCG studies for symptomatic infection revealed a non-linear trend against Omicron with a peak of 67.3%, declining to 27.1% after 25 weeks after a booster dose. The mean of VE for hospitalization over time started to decrease after four weeks against Omicron and after eight weeks against Delta. The VE reached a peak at week eight (96.0%) and started to decline with a VE of 93.3% after 20 weeks after the booster dose against Delta. It was 90.8% at week four and decreased to 73.4% after 25 weeks after the booster dose against Omicron. VE in the C2DCG studies demonstrated more decreases in outcomes over time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings showed a tendency to decrease effectiveness over time based on outcomes and variants. The early protection levels were lower in Omicron. Moreover, the VE decrease over time was stronger in Omicron compared to the Delta variant.</AbstractText><CopyrightInformation>© 2024 The Author(s); Published by Hamadan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Farideh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1611-3806</Identifier><AffiliationInfo><Affiliation>Student Research Committee, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahardoust</LastName><ForeName>Mansour</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sera</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Statistics, Computer Science and Applications 'G.Parenti', University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amirabadizadeh</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, 9717113163, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allahyari</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, Doctor of Veterinary Medicine Student, Faculty of Veterinary Medicine, Garmsar Branch, Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ssentongod</LastName><ForeName>Paddy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karami</LastName><ForeName>Manochehr</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemi Nazari</LastName><ForeName>Seyed Saeed</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-0883-3408</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>J Res Health Sci</MedlineTA><NlmUniqueID>101480094</NlmUniqueID><ISSNLinking>2228-7795</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine booster shot</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Vaccine efficacy</Keyword></KeywordList><CoiStatement> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>8</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39431651</ArticleId><ArticleId IdType="pmc">PMC11492529</ArticleId><ArticleId IdType="doi">10.34172/jrhs.2024.161</ArticleId><ArticleId IdType="pii">e00626</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400–7. doi: 10.1080/21645515.2020.1804776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1804776</ArticleId><ArticleId IdType="pmc">PMC7899627</ArticleId><ArticleId IdType="pubmed">32845739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph A, Mitchell J, Barrett J, Sköld H, Taavola H, Erlanson N, et al. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Ther Adv Drug Saf. 2022;13:20420986221118972. doi: 10.1177/20420986221118972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20420986221118972</ArticleId><ArticleId IdType="pmc">PMC9424876</ArticleId><ArticleId IdType="pubmed">36052399</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831–7. doi: 10.1038/s41591-022-01699-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01699-1</ArticleId><ArticleId IdType="pmc">PMC9018410</ArticleId><ArticleId IdType="pubmed">35045566</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27(12):2127–35. doi: 10.1038/s41591-021-01548-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01548-7</ArticleId><ArticleId IdType="pmc">PMC8674129</ArticleId><ArticleId IdType="pubmed">34650248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539–48. doi: 10.1016/s1473-3099(21)00330-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00330-3</ArticleId><ArticleId IdType="pmc">PMC8221734</ArticleId><ArticleId IdType="pubmed">34174190</ArticleId></ArticleIdList></Reference><Reference><Citation> Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv [Preprint]. October 6, 2021. Available from: https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2. </Citation></Reference><Reference><Citation>Morgan RL, Florez ID. Principles of systematic reviews and meta-analyses. Methods Mol Biol. 2022;2345:1–15. doi: 10.1007/978-1-0716-1566-9_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1566-9_1</ArticleId><ArticleId IdType="pubmed">34550581</ArticleId></ArticleIdList></Reference><Reference><Citation>Penson D, Krishnaswami S, Jules A, Seroogy J, McPheeters M. Newcastle-Ottawa Quality Assessment form for Cohort Studies. Ottawa: Ottawa Hospital Research Institute; 2012.</Citation></Reference><Reference><Citation>Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. In: Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons; 2019. p. 205-28.</Citation></Reference><Reference><Citation>Ishak KJ, Platt RW, Joseph L, Hanley JA, Caro JJ. Meta-analysis of longitudinal studies. Clin Trials. 2007;4(5):525–39. doi: 10.1177/1740774507083567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774507083567</ArticleId><ArticleId IdType="pubmed">17942468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sera F, Armstrong B, Blangiardo M, Gasparrini A. An extended mixed-effects framework for meta-analysis. Stat Med. 2019;38(29):5429–44. doi: 10.1002/sim.8362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8362</ArticleId><ArticleId IdType="pubmed">31647135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore) 2019;98(23):e15987. doi: 10.1097/md.0000000000015987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000015987</ArticleId><ArticleId IdType="pmc">PMC6571372</ArticleId><ArticleId IdType="pubmed">31169736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjerdevik M, Heuch I. Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14:109. doi: 10.1186/1471-2288-14-109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-109</ArticleId><ArticleId IdType="pmc">PMC4193136</ArticleId><ArticleId IdType="pubmed">25245217</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med. 2022;386(20):1910–21. doi: 10.1056/NEJMoa2200674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XY, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910–9. doi: 10.1080/22221751.2022.2088406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2088406</ArticleId><ArticleId IdType="pmc">PMC9347473</ArticleId><ArticleId IdType="pubmed">35686572</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES, et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat Med. 2022;28(4):838–43. doi: 10.1038/s41591-022-01701-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01701-w</ArticleId><ArticleId IdType="pmc">PMC9018414</ArticleId><ArticleId IdType="pubmed">35140406</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Júnior JB, Penna GO, Werneck GL, et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nat Commun. 2022;13(1):4154. doi: 10.1038/s41467-022-31839-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31839-7</ArticleId><ArticleId IdType="pmc">PMC9289933</ArticleId><ArticleId IdType="pubmed">35851597</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA 2 variant infection, severe illness, and death. BMC Med. 2022;20(1):400. doi: 10.1186/s12916-022-02606-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02606-8</ArticleId><ArticleId IdType="pmc">PMC9583051</ArticleId><ArticleId IdType="pubmed">36266697</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100. doi: 10.1016/s0140-6736(21)02249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02249-2</ArticleId><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Patel MM, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118–24. doi: 10.15585/mmwr.mm7104a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7104a2</ArticleId><ArticleId IdType="pmc">PMC9351530</ArticleId><ArticleId IdType="pubmed">35085218</ArticleId></ArticleIdList></Reference><Reference><Citation>Korves C, Izurieta HS, Smith J, Zwain GM, Powell EI, Balajee A, et al. Relative effectiveness of booster vs 2-dose mRNA COVID-19 vaccination in the Veterans Health Administration: self-controlled risk interval analysis. Vaccine. 2022;40(33):4742–7. doi: 10.1016/j.vaccine.2022.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.047</ArticleId><ArticleId IdType="pmc">PMC9212417</ArticleId><ArticleId IdType="pubmed">35773122</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, Elorreaga OA, Mayta-Tristán P, et al. Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: a nested case-control study using national population data. Vaccine. 2022;40(45):6512–9. doi: 10.1016/j.vaccine.2022.09.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.09.066</ArticleId><ArticleId IdType="pmc">PMC9515342</ArticleId><ArticleId IdType="pubmed">36202642</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Casado I, Navascués A, Burgui C, et al. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA1-predominant period, Navarre, Spain, January to March 2022. Euro Surveill. 2023;28(5):2200337. doi: 10.2807/1560-7917.es.2023.28.5.2200337.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2023.28.5.2200337</ArticleId><ArticleId IdType="pmc">PMC9896606</ArticleId><ArticleId IdType="pubmed">36729113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA1 and BA2 subvariants in Qatar. Nat Commun. 2022;13(1):3082. doi: 10.1038/s41467-022-30895-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30895-3</ArticleId><ArticleId IdType="pmc">PMC9163167</ArticleId><ArticleId IdType="pubmed">35654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. COVID-19 vaccine effectiveness against the Omicron (B11529) variant. N Engl J Med. 2022;386(16):1532–46. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiani M, Puopolo M, Filia A, Sacco C, Mateo-Urdiales A, Spila Alegiani S, et al. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥ 60 years and other high-risk groups during predominant circulation of the Delta variant in Italy, 19 July to 12 December 2021. Expert Rev Vaccines. 2022;21(7):975–82. doi: 10.1080/14760584.2022.2064280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2064280</ArticleId><ArticleId IdType="pmc">PMC9115794</ArticleId><ArticleId IdType="pubmed">35389748</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639–51. doi: 10.1001/jama.2022.0470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139–45. doi: 10.15585/mmwr.mm7104e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7104e3</ArticleId><ArticleId IdType="pmc">PMC9351525</ArticleId><ArticleId IdType="pubmed">35085224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–63. doi: 10.15585/mmwr.mm7107e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7107e2</ArticleId><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, et al. Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad26COV2S (Janssen [Johnson &amp; Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):495–502. doi: 10.15585/mmwr.mm7113e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7113e2</ArticleId><ArticleId IdType="pmc">PMC8979598</ArticleId><ArticleId IdType="pubmed">35358170</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Xu Y, Zwain GM, Izurieta HS, Korves C, Powell EI, Smith J, et al. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. BMJ Open. 2022;12(8):e063935. doi: 10.1136/bmjopen-2022-063935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-063935</ArticleId><ArticleId IdType="pmc">PMC9352567</ArticleId><ArticleId IdType="pubmed">35922100</ArticleId></ArticleIdList></Reference><Reference><Citation>Suphanchaimat R, Nittayasoot N, Jiraphongsa C, Thammawijaya P, Bumrungwong P, Tulyathan A, et al. Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: a nationwide test-negative matched case-control study. Vaccines (Basel) 2022;10(7):1080. doi: 10.3390/vaccines10071080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071080</ArticleId><ArticleId IdType="pmc">PMC9315782</ArticleId><ArticleId IdType="pubmed">35891245</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Levy ME, Gaglani M, Irving SA, Stockwell M, Dascomb K, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA1 and BA2/BA2121 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931–9. doi: 10.15585/mmwr.mm7129e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7129e1</ArticleId><ArticleId IdType="pmc">PMC9310634</ArticleId><ArticleId IdType="pubmed">35862287</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831–7. doi: 10.1038/s41591-022-01699-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01699-1</ArticleId><ArticleId IdType="pmc">PMC9018410</ArticleId><ArticleId IdType="pubmed">35045566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsebom FC, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nat Commun. 2022;13(1):7688. doi: 10.1038/s41467-022-35168-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35168-7</ArticleId><ArticleId IdType="pmc">PMC9744366</ArticleId><ArticleId IdType="pubmed">36509743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION Network: test negative, case-control study. BMJ. 2022;379:e072141. doi: 10.1136/bmj-2022-072141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072141</ArticleId><ArticleId IdType="pmc">PMC9527398</ArticleId><ArticleId IdType="pubmed">36191948</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, et al. Vaccine effectiveness against Delta, Omicron BA1, and BA2 in a highly vaccinated Asian setting: a test-negative design study. Clin Microbiol Infect. 2023;29(1):101–6. doi: 10.1016/j.cmi.2022.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.08.002</ArticleId><ArticleId IdType="pmc">PMC9398552</ArticleId><ArticleId IdType="pubmed">36028091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T, Shah SA, Robertson C, Sanchez M, Katikireddi SV, de Araujo Oliveira V, et al. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: a test-negative design case-control study. PLoS Med. 2023;20(1):e1004156. doi: 10.1371/journal.pmed.1004156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004156</ArticleId><ArticleId IdType="pmc">PMC9879484</ArticleId><ArticleId IdType="pubmed">36630477</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al. Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA4 and BA5 sublineage periods. JAMA Netw Open. 2023;6(3):e232598. doi: 10.1001/jamanetworkopen.2023.2598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.2598</ArticleId><ArticleId IdType="pmc">PMC10018321</ArticleId><ArticleId IdType="pubmed">36920396</ArticleId></ArticleIdList></Reference><Reference><Citation>Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, et al. Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during Delta and Omicron predominance in Thailand: a test-negative, case-control study. Lancet Reg Health Southeast Asia. 2023;10:100121. doi: 10.1016/j.lansea.2022.100121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2022.100121</ArticleId><ArticleId IdType="pmc">PMC9705195</ArticleId><ArticleId IdType="pubmed">36465090</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamandjou Tchuem CR, Auvigne V, Vaux S, Montagnat C, Paireau J, Monnier Besnard S, et al. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. Vaccine. 2023;41(13):2280–8. doi: 10.1016/j.vaccine.2023.02.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.062</ArticleId><ArticleId IdType="pmc">PMC9968619</ArticleId><ArticleId IdType="pubmed">36870880</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. Nat Commun. 2023;14(1):1273. doi: 10.1038/s41467-023-36566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36566-1</ArticleId><ArticleId IdType="pmc">PMC9990563</ArticleId><ArticleId IdType="pubmed">36882416</ArticleId></ArticleIdList></Reference><Reference><Citation>Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. Coronavirus disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during Delta-dominant and Omicron-dominant periods in Japan: a multicenter prospective case-control study (factors associated with SARS-CoV-2 infection and the effectiveness of COVID-19 vaccines study) Clin Infect Dis. 2023;76(3):e108–15. doi: 10.1093/cid/ciac635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac635</ArticleId><ArticleId IdType="pmc">PMC9384625</ArticleId><ArticleId IdType="pubmed">35918782</ArticleId></ArticleIdList></Reference><Reference><Citation>Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern Med. 2022;182(2):179–84. doi: 10.1001/jamainternmed.2021.7382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.7382</ArticleId><ArticleId IdType="pmc">PMC8634151</ArticleId><ArticleId IdType="pubmed">34846533</ArticleId></ArticleIdList></Reference><Reference><Citation>Patalon T, Saciuk Y, Peretz A, Perez G, Lurie Y, Maor Y, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun. 2022;13(1):3203. doi: 10.1038/s41467-022-30884-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30884-6</ArticleId><ArticleId IdType="pmc">PMC9184525</ArticleId><ArticleId IdType="pubmed">35680872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022;22(7):959–66. doi: 10.1016/s1473-3099(22)00141-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00141-4</ArticleId><ArticleId IdType="pmc">PMC9033213</ArticleId><ArticleId IdType="pubmed">35468332</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, et al. Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(15):549–55. doi: 10.15585/mmwr.mm7115e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7115e2</ArticleId><ArticleId IdType="pmc">PMC9020856</ArticleId><ArticleId IdType="pubmed">35421077</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the Delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–92. doi: 10.1080/22221751.2022.2037398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2037398</ArticleId><ArticleId IdType="pmc">PMC8856087</ArticleId><ArticleId IdType="pubmed">35114893</ArticleId></ArticleIdList></Reference><Reference><Citation>Suah JL, Tng BH, Tok PSK, Husin M, Thevananthan T, Peariasamy KM, et al. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. Emerg Microbes Infect. 2022;11(1):1343–5. doi: 10.1080/22221751.2022.2072773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2072773</ArticleId><ArticleId IdType="pmc">PMC9132393</ArticleId><ArticleId IdType="pubmed">35499301</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of primary series and booster doses against COVID-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022;379:e072065. doi: 10.1136/bmj-2022-072065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072065</ArticleId><ArticleId IdType="pmc">PMC9551237</ArticleId><ArticleId IdType="pubmed">36220174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani OT, Hitchings MD, de Melo RL, de França GV, de Fátima Rangel Fernandes C, Lind ML, et al. Effectiveness of an inactivated COVID-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun. 2022;13(1):5536. doi: 10.1038/s41467-022-33169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33169-0</ArticleId><ArticleId IdType="pmc">PMC9537178</ArticleId><ArticleId IdType="pubmed">36202800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind ML, Robertson AJ, Silva J, Warner F, Coppi AC, Price N, et al. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: a test-negative case-control analysis. PLoS Med. 2022;19(12):e1004136. doi: 10.1371/journal.pmed.1004136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004136</ArticleId><ArticleId IdType="pmc">PMC9714718</ArticleId><ArticleId IdType="pubmed">36454733</ArticleId></ArticleIdList></Reference><Reference><Citation>Surie D, Bonnell L, Adams K, Gaglani M, Ginde AA, Douin DJ, et al. Effectiveness of monovalent mRNA vaccines against COVID-19-associated hospitalization among immunocompetent adults during BA1/BA2 and BA4/BA5 predominant periods of SARS-CoV-2 Omicron variant in the United States - IVY Network, 18 states, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327–34. doi: 10.15585/mmwr.mm7142a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7142a3</ArticleId><ArticleId IdType="pmc">PMC9590291</ArticleId><ArticleId IdType="pubmed">36264830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, et al. Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? Emerg Microbes Infect. 2023;12(1):2174779. doi: 10.1080/22221751.2023.2174779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2174779</ArticleId><ArticleId IdType="pmc">PMC9936995</ArticleId><ArticleId IdType="pubmed">36715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Richterman A, Behrman A, Brennan PJ, O’Donnell JA, Snider CK, Chaiyachati KH. Durability of severe acute respiratory syndrome coronavirus 2 messenger RNA booster vaccine protection against Omicron among healthcare workers with a vaccine mandate. Clin Infect Dis. 2023;76(3):e319–26. doi: 10.1093/cid/ciac454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac454</ArticleId><ArticleId IdType="pmc">PMC9214168</ArticleId><ArticleId IdType="pubmed">35666508</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatman-Freedman A, Bromberg M, Hershkovitz Y, Sefty H, Kaufman Z, Dichtiar R, et al. Effectiveness of BNT162b2 vaccine booster against SARS-CoV-2 infection and breakthrough complications, Israel. Emerg Infect Dis. 2022;28(5):948–56. doi: 10.3201/eid2805.220141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2805.220141</ArticleId><ArticleId IdType="pmc">PMC9045419</ArticleId><ArticleId IdType="pubmed">35361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman JG, Makov-Assif M, Reis BY, Netzer D, Balicer RD, Dagan N, et al. Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel. Nat Commun. 2022;13(1):2202. doi: 10.1038/s41467-022-29858-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29858-5</ArticleId><ArticleId IdType="pmc">PMC9033865</ArticleId><ArticleId IdType="pubmed">35459237</ArticleId></ArticleIdList></Reference><Reference><Citation>Björk J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022. Euro Surveill 2022;27(18). 10.2807/1560-7917.es.2022.27.18.2200322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2022.27.18.2200322</ArticleId><ArticleId IdType="pmc">PMC9074397</ArticleId><ArticleId IdType="pubmed">35514304</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am. 2022;9:100198. doi: 10.1016/j.lana.2022.100198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100198</ArticleId><ArticleId IdType="pmc">PMC8841530</ArticleId><ArticleId IdType="pubmed">35187521</ArticleId></ArticleIdList></Reference><Reference><Citation>Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø G, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021. BMC Med. 2022;20(1):278. doi: 10.1186/s12916-022-02480-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02480-4</ArticleId><ArticleId IdType="pmc">PMC9436448</ArticleId><ArticleId IdType="pubmed">36050718</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyauchi S, Hiyama T, Nakano Y, Yoshida M, Yoshino A, Miyake Y, et al. Real-world effectiveness of a booster dose of the COVID-19 vaccines among Japanese university students. Vaccines (Basel) 2022;10(8):1283. doi: 10.3390/vaccines10081283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081283</ArticleId><ArticleId IdType="pmc">PMC9413816</ArticleId><ArticleId IdType="pubmed">36016171</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaishi T, Kushimoto S, Katori Y, Sugawara N, Egusa H, Igarashi K, et al. Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan. Sci Rep. 2022;12(1):13589. doi: 10.1038/s41598-022-17990-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17990-7</ArticleId><ArticleId IdType="pmc">PMC9365759</ArticleId><ArticleId IdType="pubmed">35948626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonmezer MC, Dizman GT, Erul E, Sahin TK, Saricaoglu T, Alp A, et al. Relative vaccine effectiveness of the third dose of CoronaVac or BNT162b2 following a two-dose CoronaVac regimen: a prospective observational cohort study from an adult vaccine center in Turkey. Vaccines (Basel) 2022;10(7):1140. doi: 10.3390/vaccines10071140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071140</ArticleId><ArticleId IdType="pmc">PMC9322864</ArticleId><ArticleId IdType="pubmed">35891304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothberg MB, Kim P, Shrestha NK, Kojima L, Tereshchenko LG. Protection against the Omicron variant offered by previous severe acute respiratory syndrome coronavirus 2 infection: a retrospective cohort study. Clin Infect Dis. 2023;76(3):e142–7. doi: 10.1093/cid/ciac604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac604</ArticleId><ArticleId IdType="pmc">PMC9384480</ArticleId><ArticleId IdType="pubmed">35867678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M, Krutikov M, Nacer-Laidi H, Azmi B, Palmer T, Giddings R, et al. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Healthy Longev. 2022;3(7):e470–80. doi: 10.1016/s2666-7568(22)00147-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-7568(22)00147-7</ArticleId><ArticleId IdType="pmc">PMC9252508</ArticleId><ArticleId IdType="pubmed">35813279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss Z, Wittmann I, Polivka L, Surján G, Surján O, Barcza Z, et al. Nationwide effectiveness of first and second SARS-CoV2 booster vaccines during the Delta and Omicron pandemic waves in Hungary (HUN-VE 2 study) Front Immunol. 2022;13:905585. doi: 10.3389/fimmu.2022.905585.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.905585</ArticleId><ArticleId IdType="pmc">PMC9260843</ArticleId><ArticleId IdType="pubmed">35812442</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002–10. doi: 10.1016/s1473-3099(22)00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00146-3</ArticleId><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–806. doi: 10.1016/s2214-109x(22)00112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(22)00112-7</ArticleId><ArticleId IdType="pmc">PMC9034854</ArticleId><ArticleId IdType="pubmed">35472300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Q, Zheng D, Yu B, Tan X, Chen Q, Wang L, et al. Effectiveness of inactivated COVID-19 vaccines against COVID-19 caused by the SARS-CoV-2 Delta and Omicron variants: a retrospective cohort study. Vaccines (Basel) 2022;10(10):1753. doi: 10.3390/vaccines10101753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101753</ArticleId><ArticleId IdType="pmc">PMC9611172</ArticleId><ArticleId IdType="pubmed">36298618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kislaya I, Machado A, Magalhães S, Rodrigues AP, Franco R, Leite PP, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Euro Surveill. 2022;27(37):2200697. doi: 10.2807/1560-7917.es.2022.27.37.2200697.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2022.27.37.2200697</ArticleId><ArticleId IdType="pmc">PMC9479470</ArticleId><ArticleId IdType="pubmed">36111555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA1) and Delta (B16172) variants: a case-case study based on electronic health records. Influenza Other Respir Viruses. 2023;17(3):e13121. doi: 10.1111/irv.13121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13121</ArticleId><ArticleId IdType="pmc">PMC10014519</ArticleId><ArticleId IdType="pubmed">36935845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang NN, So HC, Cowling BJ, Leung GM, Ip DK. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 Omicron BA2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421–34. doi: 10.1016/s1473-3099(22)00732-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00732-0</ArticleId><ArticleId IdType="pmc">PMC9744442</ArticleId><ArticleId IdType="pubmed">36521506</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos CV, de Noronha TG, Werneck GL, Struchiner CJ, Villela DA. Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a retrospective observational study. Lancet Reg Health Am. 2023;17:100418. doi: 10.1016/j.lana.2022.100418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100418</ArticleId><ArticleId IdType="pmc">PMC9779315</ArticleId><ArticleId IdType="pubmed">36575682</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Miraglia JL, Malheiros DT, Guozhang Y, Teich VD, da Silva Victor E, et al. Effectiveness of heterologous coronavirus disease 2019 (COVID-19) vaccine booster dosing in Brazilian healthcare workers, 2021. Clin Infect Dis. 2023;76(3):e360–6. doi: 10.1093/cid/ciac430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac430</ArticleId><ArticleId IdType="pmc">PMC9213833</ArticleId><ArticleId IdType="pubmed">35639918</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamal JM, Appana S, Wang M, Leon-Novelo L, Bakota E, Ye Y, et al. Trends and correlates of breakthrough infections with SARS-CoV-2. Front Public Health. 2022;10:856532. doi: 10.3389/fpubh.2022.856532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.856532</ArticleId><ArticleId IdType="pmc">PMC9127615</ArticleId><ArticleId IdType="pubmed">35619825</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, José Sierra M, Limia A, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 Omicron (B11529) variant in Spain: a nationwide cohort study. Lancet Infect Dis. 2022;22(9):1313–20. doi: 10.1016/s1473-3099(22)00292-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00292-4</ArticleId><ArticleId IdType="pmc">PMC9162477</ArticleId><ArticleId IdType="pubmed">35658998</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster Y, Benenson S, Nir-Paz R, Buda I, Cohen MJ. The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis. Clin Microbiol Infect 2022;28(5):735.e1-735.e3. 10.1016/j.cmi.2022.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.019</ArticleId><ArticleId IdType="pmc">PMC8820100</ArticleId><ArticleId IdType="pubmed">35143997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393–400. doi: 10.1056/NEJMoa2114255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Sergienko R, Hammerman A. BNT162b2 vaccine booster and COVID-19 mortality Reply. N Engl J Med. 2022;386(10):1000–1. doi: 10.1056/NEJMc2120044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2120044</ArticleId><ArticleId IdType="pubmed">35139268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, et al. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open. 2022;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.28900</ArticleId><ArticleId IdType="pmc">PMC9419014</ArticleId><ArticleId IdType="pubmed">36018588</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti EV, Whiting K, Lucca A, Poon C, Jani K, McMillen T, et al. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022. Clin Microbiol Infect. 2022;28(12):1624–8. doi: 10.1016/j.cmi.2022.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.07.017</ArticleId><ArticleId IdType="pmc">PMC9345790</ArticleId><ArticleId IdType="pubmed">35931373</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022;386(19):1804–16. doi: 10.1056/NEJMoa2200797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200797</ArticleId><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta HB, Li S, Goodwin JS. Effectiveness of COVID-19 booster on the risk of hospitalization among Medicare beneficiaries. Mayo Clin Proc. 2022;97(10):1780–93. doi: 10.1016/j.mayocp.2022.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2022.06.029</ArticleId><ArticleId IdType="pmc">PMC9273609</ArticleId><ArticleId IdType="pubmed">36202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Zhang Y, Wang F, Wu D, Qian ZH, Zhang R, et al. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. BMJ Open. 2022;12(11):e063919. doi: 10.1136/bmjopen-2022-063919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-063919</ArticleId><ArticleId IdType="pmc">PMC9659710</ArticleId><ArticleId IdType="pubmed">36368753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Bohnert ASB, O’Hare AM, Boyko EJ, Maciejewski ML, Smith VA, et al. Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the Omicron (B11529) variant era. Ann Intern Med. 2022;175(12):1693–706. doi: 10.7326/m22-1856.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m22-1856</ArticleId><ArticleId IdType="pmc">PMC9575390</ArticleId><ArticleId IdType="pubmed">36215715</ArticleId></ArticleIdList></Reference><Reference><Citation>Laake I, Skodvin SN, Blix K, Caspersen IH, Gjessing HK, Juvet LK, et al. Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort. J Infect Dis. 2022;226(11):1924–33. doi: 10.1093/infdis/jiac419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac419</ArticleId><ArticleId IdType="pmc">PMC9620770</ArticleId><ArticleId IdType="pubmed">36259543</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative vaccine effectiveness of a severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine booster dose against the Omicron variant. Clin Infect Dis. 2022;75(12):2161–8. doi: 10.1093/cid/ciac328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac328</ArticleId><ArticleId IdType="pmc">PMC11487159</ArticleId><ArticleId IdType="pubmed">35511586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MT, Dhaliwal SS, Balakrishnan V, Nordin F, Norazmi MN, Tye GJ. Effectiveness of booster vaccinations on the control of COVID-19 during the spread of Omicron variant in Malaysia. Int J Environ Res Public Health. 2023;20(2):1647. doi: 10.3390/ijerph20021647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph20021647</ArticleId><ArticleId IdType="pmc">PMC9861773</ArticleId><ArticleId IdType="pubmed">36674401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CY, Chang JC, Chen SL, Chang HH, Lin AT, Yen AM, et al. Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Naïve infection. J Infect Public Health. 2023;16(1):55–63. doi: 10.1016/j.jiph.2022.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.11.028</ArticleId><ArticleId IdType="pmc">PMC9708104</ArticleId><ArticleId IdType="pubmed">36470007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L, Wiegand RE, Oyalowo AC, Bull-Otterson L, Egwuogu H, Thompson T, et al. Relative effectiveness of coronavirus disease 2019 vaccination and booster dose combinations among 189 million vaccinated adults during the early severe acute respiratory syndrome coronavirus 2 Omicron period-United States, 1 January 2022 to 31 March 2022. Clin Infect Dis. 2023;76(10):1753–60. doi: 10.1093/cid/ciad063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad063</ArticleId><ArticleId IdType="pmc">PMC11179631</ArticleId><ArticleId IdType="pubmed">36750643</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, et al. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza Other Respir Viruses. 2023;17(3):e13104. doi: 10.1111/irv.13104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13104</ArticleId><ArticleId IdType="pmc">PMC9975792</ArticleId><ArticleId IdType="pubmed">36875208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA1 and BA2 subvariants in Qatar. Nat Commun. 2022;13(1):3082. doi: 10.1038/s41467-022-30895-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30895-3</ArticleId><ArticleId IdType="pmc">PMC9163167</ArticleId><ArticleId IdType="pubmed">35654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: current insights and future directions. Microbiol Res. 2022;265:127204. doi: 10.1016/j.micres.2022.127204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micres.2022.127204</ArticleId><ArticleId IdType="pmc">PMC9482093</ArticleId><ArticleId IdType="pubmed">36152612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Yu Y, Zhao S, He D. A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Math Biosci Eng. 2022;19(10):10361–73. doi: 10.3934/mbe.2022485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2022485</ArticleId><ArticleId IdType="pubmed">36031998</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero N, Nieto MA, Suarez-Zamora DA, Arias-Amaya JS, Duran D, González-Teshima LY, et al. Effectiveness and safety of covid-19 vaccines available in middle-income countries to prevent infection, hospitalisation, and death due to COVID-19: a systematic review and meta-analysis. Preprint. Posted online February 3, 2023. SSRN. 10.2139/ssrn.4344634.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4344634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N, Joyal-Desmarais K, Ribeiro PA, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439–52. doi: 10.1016/s2213-2600(23)00015-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(23)00015-2</ArticleId><ArticleId IdType="pmc">PMC9917454</ArticleId><ArticleId IdType="pubmed">36780914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>